2023 World Conference on Lung Cancer (Posters)-EP08.02. Clinicopathological Analyses for Predicting Survival After Salvage Surgery for Initially Unresectable Lung Cancer

EP08.02. Clinicopathological Analyses for Predicting Survival After Salvage Surgery for Initially Unresectable Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the prognosis of patients who underwent salvage lung resection for initially unresectable lung cancer and to identify clinicopathological predictors of postoperative survival. The researchers retrospectively reviewed clinicopathological data of 25 consecutive patients who underwent salvage lung resection between 2010 and 2022. The median follow-up time was 41 months. The most common histologic type was adenocarcinoma, and the most frequent initial stage was clinical stage IV. Salvage lung resection was performed for residual or regrowing primary tumors. Lobectomy was the most common procedure, and complete R0 resection was achieved in most cases. A major pathologic response (MPR) was observed in some patients, and a pathological complete response was achieved in a few. The 3-year overall and recurrence-free survival rates were 81.7% and 44.1%, respectively. There was no significant difference in overall survival between patients with and without MPR or residual and regrowing lesions. However, patients with high stroma proportions in the resected specimen showed significantly better overall survival than those with low stroma proportions. The researchers concluded that salvage surgery in their cohort was performed safely without postoperative mortality and showed a relatively favorable outcome. The proportion of stroma in the resected specimen may serve as a useful prognostic indicator after salvage surgery for non-small cell lung cancer.

Asset Subtitle

Naoyuki Oka

Meta Tag

Speaker Naoyuki Oka

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

salvage lung resection

unresectable lung cancer

clinicopathological predictors

postoperative survival

adenocarcinoma

lobectomy

complete R0 resection

major pathologic response

3-year overall survival

non-small cell lung cancer